TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19394033
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (OR)
Study: 15151947
Drug: SRL172 (killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL172 (killed Mycobacterium vaccae) with chemotherapy
Study: 12593029
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (cefotaxime, ceftriaxone, amoxicillin/clavulanate)
Study: 9649142
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m² i.v. every 3 weeks
Study: 9649142
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m² i.v. every 3 weeks
Study: 2642543
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Study: 2642543
Drug: 18 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Study: 55529
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg orally three times a week on alternate weeks)
Study: 31415063
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise intervention (strength/resistance training twice per week and 180 minutes of walking per week)
Study: 21276962
Drug: Wait-list group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list group (treatment-as-usual, TAU)
Study: 18759522
Drug: Dalteparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (100 IU/kg subcutaneously twice a day for 10 days, then 100 IU/kg once a day for another 10 days)
Study: 18759522
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily throughout the study)
Study: 12374537
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of a standard sun protection factor 15+ broad-spectrum retail sunscreen to the head and neck, arms, and hands.
Study: 499311
Drug: Desmethylimipramine (DMI)
Normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desmethylimipramine (DMI) 75 mg daily for 3 days
Study: 499311
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 mg
Study: 499311
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant drugs
Study: 31022754
Drug: Plasma sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma sodium concentration ≤136 mmol/L
Study: 29460813
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg vitamin B12 daily for 8 weeks
Study: 26790758
Drug: LPS administration
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS administration (0.4–0.8 ng/kg body weight)
Study: 20642382
Drug: drospirenone +
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drospirenone + ethinylestradiol + oral L-arginine (4 g × 2/daily)
Study: 8444226
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg of 20% albumin infusion
Study: 8444226
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg of maintenance fluids (placebo)
Study: 3942669
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of water with diazepam tablets (group A)
Study: 3942669
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of water with diazepam tablets (group B)
Study: 27354129
Drug: Sulfasalazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1000 mg orally twice daily during and for 4 weeks after RT)
Study: 27354129
Drug: Placebo (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally twice daily during and for 4 weeks after RT)
Study: 20080466
Drug: VEGF-targeting drugs
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF-targeting drugs (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib)
Study: 20080466
Drug: PI3K‐mTOR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3K‐mTOR inhibitors (temsirolimus, everolimus)
Study: 15812585
Drug: Gonyautoxin infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonyautoxin infiltration (100 units in 1 ml)
Study: 8882257
Drug: Aspiration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration of 2 ml of patient's blood into propofol
Study: 8882257
Drug: Lignocaine 20
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 20 mg added to propofol
Study: 8882257
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml added to propofol
Study: 3918653
Drug: 16.64 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.64 mg glyceryl trinitrate
Study: 3918653
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg isosorbide dinitrate
Study: 29808262
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of 0.25% levobupivacaine + 1 ml (20 mg) nalbuphine
Study: 29808262
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of 0.5% levobupivacaine + 1 ml normal saline
Study: 29808262
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of 0.25% levobupivacaine + 1 ml normal saline
Study: 26939572
Drug: GSK672 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK672 90 mg twice daily
Study: 26939572
Drug: GSK672 10-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK672 10-90 mg twice daily
Study: 23819250
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment and routine western medicine
Study: 21838089
Drug: Micronized tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized tretinoin gel 0.05%
Study: 19480872
Drug: Hippotherapy (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (12 weekly sessions)
Study: 27016618
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg IV-TXA
Study: 27016618
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg IV-TXA
Study: 24193993
Drug: 100 or
Normalized name: Stalevo 100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 200 mg of lidocaine injections
Study: 24193993
Drug: saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline injections
Study: 23535609
Drug: Prenatal lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal lipid-based nutrient supplements (LNSs)
Study: 23535609
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient tablets
Study: 18219348
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) daily for 20 days
Study: 21033082
Drug: Taurine treatment
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine treatment for NAFLD
Study: 16282543
Drug: PCK1‐232G/G genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCK1‐232G/G genotype
Study: 7990065
Drug: Non-hypnotic sessions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypnotic sessions (3 sessions)
Study: 26980216
Drug: Percutaneous para‐aneurysmal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous para‐aneurysmal saline injection
Study: 22337474
Drug: Dead Sea
Normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead Sea salt (DSS) irrigations and DSS nasal spray
Study: 22337474
Drug: Fluticasone spray
Normalized name: fluticasone Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone spray and hypertonic saline irrigation and spray
Study: 18419328
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel (11 mL)
Study: 18419328
Drug: 40% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% DMSO with lidocaine (10 mL)
Study: 12463727
Drug: Roxifiban (XV459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (XV459) 0.5 to 1.25 mg daily for 7 to 10 days
Study: 10348512
Drug: mylohyoid nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mylohyoid nerve block + IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine + 3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 10348512
Drug: mock mylohyoid
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: mock mylohyoid nerve block + IAN block (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 10348512
Drug: mylohyoid nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mylohyoid nerve block + mock IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 8622107
Drug: Isepamicin 15
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 15 mg/kg once daily
Study: 2188770
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (10, 50, 150, and 500 IU/kg) administered intravenously
Study: 2188770
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (1000 IU/kg) administered intravenously in an open manner
Study: 2188770
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (various doses)
Study: 6994369
Drug: Iso‐Ameritrat (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso‐Ameritrat (2.5 mg Isosorbide Dinitrate and 10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Study: 6994369
Drug: Ameritrat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ameritrat (10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Study: 30258854
Drug: Higher percentage
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher percentage of daily energy intake from fats
Study: 24374821
Drug: BMS‐986001 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐986001 (10, 30, 100, 300, 600, and 900 mg fed; 100 and 300 mg fasted)
Study: 19768533
Drug: Concomitant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant docetaxel (75 mg/m2 on day 8) plus gemcitabine (1,000 mg/m2 on days 1 + 8) for 8 cycles
Study: 19768533
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel (100 mg/m2 on day 1 for 4 cycles) followed by gemcitabine (1,250 mg/m2 on days 1 + 8 for 4 cycles)
Study: 17689809
Drug: Probabilistic threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probabilistic threshold technique (TT) for measuring maximum acceptable risk increments (MARI) for adverse effects from OA medication.
Study: 16344838
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended release (MAS XR) 10-60 mg/day (mean dose: 37.2 mg/day)
Study: 11488519
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 over 1 hour
Study: 11488519
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 over 3 hours
Study: 11488519
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paclitaxel and carboplatin
Study: 10085709
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of hemodialysis treatment
Study: 1098727
Drug: Levamisole 50
Normalized name: levamisole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 50 mg three times a day by mouth for three days every fortnight, starting three days before surgery
Study: 19307225
Drug: Antireflux treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antireflux treatment
Study: 8458448
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) depot (Enantone Depot, Takeda, Italy) administered preoperatively
Study: 2429085
Drug: Methyldopa (500‐1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500‐1000 mg daily)
Study: 30565854
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg day−1 for 4 weeks
Study: 24714541
Drug: HMB-FA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA (3 g) and ATP (400 mg) supplementation
Study: 24706266
Drug: Synbiotic bread
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic bread (1 × 10(8) CFU Lactobacillus sporogenes and 0.07 g inulin per 1 g)
Study: 24706266
Drug: Probiotic bread
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic bread (1 × 10(8) CFU Lactobacillus sporogenes per 1 g)
Study: 21450196
Drug: Mental practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice intervention embedded in regular therapy
Study: 21450196
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy as usual (control group)
Study: 20450590
Drug: Calcium-Magnesium infusion
Normalized name: CALCIUM/MAGNESIUM/POTASSIUM/SODIUM OXYBATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-Magnesium infusion
Study: 20450590
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (normal saline)
Study: 17364394
Drug: DAART (Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAART (Directly Administered Antiretroviral Therapy)
Study: 10325288
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (diagnostic laparoscopy only, 47 patients)
Study: 8961453
Drug: Pain facility
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain facility treatment
Study: 1763680
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no immuno-suppressive treatment)
Study: 29530858
Drug: Iclaprim (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim (80 mg) administered intravenously every 12 h for 5 to 14 days
Study: 29530858
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg of body weight) administered intravenously every 12 h for 5 to 14 days
Study: 26560249
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery pressure guided management (treatment group)
Study: 20546269
Drug: Euglycaemia (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5.0 mmol/l)
Study: 20546269
Drug: Hyperglycaemia (11.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (11.0 mmol/l)
Study: 19034035
Drug: Clopidogrel 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 37.5 mg
Study: 9507380
Drug: Leukapheresis initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Leukapheresis initiated based on CD34+ blood level exceeding 20,000 CD34+/ml
Study: 9507380
Drug: Leukapheresis for
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukapheresis for high-level mobilizers (> 80,000 CD34+ cells/ml)
Study: 9507380
Drug: Leukapheresis for
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukapheresis for low-level mobilizers (< 40,000 CD34+ cells/ml)
Study: 8064949
Drug: Maloprim (pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maloprim (pyrimethamine 12.5 mg + dapsone 100 mg)
Study: 30183875
Drug: Ear acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear acupuncture (Treatment)
Study: 25042488
Drug: Chondroprotector АРТРА
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroprotector АРТРА with melaxen (melatonin 3 mg)
Study: 20647201
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment
Study: 20647201
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment starting when CD4+ T-cell count fell to 200 or less or when clinical AIDS developed
Study: 20647201
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with zidovudine, lamivudine, and efavirenz therapy
Study: 16003229
Drug: Corticosteroid rejection
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid rejection therapy in CSWD patients
Study: 11809343
Drug: HRT 1
Normalized name: FEMHRT 1/5 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 1 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every month)
Study: 11809343
Drug: HRT 2
Normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 2 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every third month)
Study: 25195125
Drug: Atorvastatin only
Normalized name: Atorvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin only
Study: 25195125
Drug: Ivabradine and
Normalized name: carvedilol and ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine and atorvastatin
Study: 25195125
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drugs
Study: 22227183
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (1,25(OH)₂D), plasma Ca²⁺, daily physical activity
Study: 1696662
Drug: verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 160 mg b.i.d.
Study: 7438948
Drug: Dibenzyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibenzyline (10 mg doses orally, four and eight hours after surgery)
Study: 28243722
Drug: Re-irradiation with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation with standard dose
Study: 24321380
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy alone (Control group)
Study: 21942813
Drug: Iron-rich bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rich bread (3-4 slices daily for 6 weeks)
Study: 21942813
Drug: Control bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control bread (3-4 slices daily for 6 weeks)
Study: 17479606
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide plus inhaled formoterol fumarate
Study: 17479606
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide and oral montelukast sodium therapy
Study: 15727375
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone intra‐articular injection
Study: 15727375
Drug: triamcinolone oral
Normalized name: triamcinolone Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone oral tablets
Study: 1362568
Drug: Taxol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol administered as a 120 h infusion at 36 mg/m2/d
Study: 1362568
Drug: Taxol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol administered as a 120 h infusion at 30 mg/m2/d
Study: 1362568
Drug: Taxol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol administered as a 120 h infusion
Study: 16028649
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment (0.25 mg/kg on days 1-7, 0.12 mg/kg on days 8-14, 0.05 mg/kg on days 15-21, 0.02 mg/kg on days 21-28)
Study: 16028649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dexamethasone treatment)
Study: 9788977
Drug: Human parathyroid
Normalized name: HUMAN PARATHYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human parathyroid hormone 1-34 (hPTH 1-34)
Study: 9788977
Drug: Markers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Markers of bone formation during the first 3 months of PTH treatment
Study: 9788977
Drug: Markers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Markers of bone resorption during the first 3 months of PTH treatment
Study: 7587796
Drug: Nicotine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (12 mg chewing gum)
Study: 2262701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoclopramide and ranitidine
Study: 7377659
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg IV, repeated doses every six hours)
Study: 31049835
Drug: High temperature
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High temperature treatment (30–40 °C) for 15 days
Study: 27133000
Drug: Standard-of-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapy with video models